| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 29 May 2026 | 4 May 2026 |
| Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Standalone and Consolidated Financial Results for 4th quarter and financial year ended 31st March 2026 and Dividend. Outcome of the Board Meeting (As per BSE Announcement dated on: 29.05.2026) | ||
| Board Meeting | 13 Feb 2026 | 22 Jan 2026 |
| Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results for the 3rd quarter and nine months ended 31st December 2025 Standalone and Consolidated Financial Results for Q3FY26 (As per BSE Announcement dated on: 13.02.2026) | ||
| Board Meeting | 13 Jan 2026 | 13 Jan 2026 |
| Outcome of Board Meeting | ||
| Board Meeting | 13 Nov 2025 | 17 Oct 2025 |
| Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results for the 2nd quarter and half year ended 30.09.2025 Standalone and Consolidated Q2 H1 FY26 Results and Press Release (As per BSE Announcement dated on: 13.11.2025) | ||
| Board Meeting | 17 Oct 2025 | 17 Oct 2025 |
| Outcome of Board Meeting Slump Sale of Companys API and Drug Intermediates Manufacturing unit situated at Ankleshwar Slump Sale of Companys API and Drug Intermediates Manufacturing unit situated at Ankleshwar | ||
| Board Meeting | 11 Aug 2025 | 24 Jul 2025 |
| Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2025 inter alia to consider and approve Standalone and Consolidated Results for Q1FY26 Standalone and Consolidated Unaudited Financial Results Financial Results (As per BSE Announcement Dated on 11.08.2025) | ||
This consolidation aims to streamline all of Ipca Group's US generics formulations under a single entity, enhancing operational efficiency.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
